Express . . . The positive results of the long-term trial of the first immunotherapy in patients with peanut allergy were positive.

▎ aimmune therapeutics announced that palforzia, a peanut allergy therapy, has achieved positive results in a long-term extended clinical trial.taking palforzia for a long time can not only make peanut allergy patients continue to desensitize to peanut protein, but also improve their quality of life.peanut allergy is the most common food allergy, and severe allergic reaction may endanger the life of patients.in general, the prevention of peanut allergy is to avoid contact with peanut products, however, because the ingredients of peanuts may appear in unexpected foods, and for allergic patients, a small amount of peanut protein can cause serious allergic reactions.this unpredictable risk is like a "sword of damocs" hanging over their heads, affecting the quality of life of patients and the daily life of family members.palforzia is the first food allergy therapy approved by FDA. Its principle is to desensitize the immune system of patients with peanut allergy by taking a small amount of peanut protein.in a phase 3 clinical trial called palisade, 67.2% of patients treated with palforzia were able to tolerate a 600 mg dose of peanut protein at the end of the 52 week course.compared with 4.0% in the placebo group.however, since this treatment is actually treating patients with allergens that cause allergies, some patients may also have side effects of peanut allergy during the treatment process.although the treatment was approved by FDA in January this year, there are still doubts about the long-term safety of the treatment and whether it can improve the quality of life of patients.at the end of palisade, patients who were able to tolerate a 300 mg dose of peanut protein were enrolled in the development label extension test called arc004.they continued to receive palforzia at a dose of 300 mg / day for 28 weeks (n = 103) and 56 weeks (n = 26), respectively. The results ofarc004 showed that 80.8% of the patients who continued to receive 56 weeks of treatment could tolerate 2000 mg peanut protein (equal to 12 peanuts) at the end of the treatment.for patients treated for 28 weeks, the figure was 49%.this means that the degree of desensitization is also improved with the extension of treatment time.moreover, the number of side effects experienced by patients was reduced by 59% (28 weeks) and 85% (56 weeks), respectively.in addition, the assessment of the quality of life of patients showed that the quality of life index of patients treated with palforzia was significantly improved in the arc004 trial. this means that the long-term use of palforzia can improve the emotional and social impact of peanut allergy on patients (such as anxiety and stress caused by worrying about peanut allergy). "we are pleased to be able to share palforzia's long-term data, which show that the immune system of patients receiving continuous treatment can improve their tolerance to allergens," said Dr. Daniel Adelman, chief medical officer of aimtune Inc. "these results are encouraging and we will continue to explore the potential benefits of oral immunotherapy for food allergy. "References: [1] aimtune announcements new palforzia ™ Data suggesting increased deprivation, improved tolerance and continuous immunity after 18 and 24 months of treatment. Retrieved March 14, 2020, from note: This article aims to introduce the progress of medical and health research, not the recommendation of treatment. if you need guidance on treatment plan, please go to a regular hospital.